Tenderwize
Back to tender search

Open-House discount agreements for Eribulin

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Aug 21, 2027 · 370 days left·Open·Supplies·Framework
Original notice title

Germany – Pharmaceutical products – Open-House Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Eribulin, ATC L01XX41 - Vertragsregionen Niedersachsen, Bremen und Sachsen-Anhalt

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

The notice requires handwritten signatures on paper originals, while only the separate file is sent by email. Missing t...

Eligibility is limited to pharmaceutical undertakings under the AMG, or a consortium of such undertakings, and local re...

No procurement documents available

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Supply-related Open-House discount agreements for the active substance Eribulin (ATC L01XX41).
  • Applies to parenteral preparations from finished medicinal products used in oncology for immediate physician administration.
Show full summary

Open-House framework-style pharmaceutical supply arrangement for Eribulin (ATC L01XX41) in Germany, covering the regions Niedersachsen/Bremen and Sachsen-Anhalt. The notice states that identical, non-exclusive discount agreements will be offered to all interested pharmaceutical companies that meet the stated eligibility conditions. Electronic submission is not allowed; signed paper originals and a separate file must be submitted. No contract value is stated.

Risks

The notice requires handwritten signatures on paper originals, while only the separate file is sent by email. Missing t...

Eligibility is limited to pharmaceutical undertakings under the AMG, or a consortium of such undertakings, and local re...

No procurement documents available

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG, or a consortium of pharmaceutical undertakings, for the offered medicinal products.
  • The company must have its seat in Germany, another EU Member State, or another EEA State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical undertakings for the offered products.

Award Criteria

Lot 1

Price criterion stated, but no weight or further detail provided.

Buyer

Location

Hannover, DEU

Identifier

AOK- Niedersachsen. Die Gesundheitskasse

Activity

Health

Lots (1)

LOT-0000

Open-House discount agreements for Eribulin

Open-House non-exclusive discount agreements for Eribulin, ATC L01XX41, for parenteral preparations used in oncology for immediate physician administration. The notice says the agreements are offered for two regional lots: Lot 1 Niedersachsen/Bremen and Lot 2 Sachsen-Anhalt. Lot-specific value, CPV, and deadline details are not separately provided in the structured data.

SuppliesFrameworkEU fundedElectronic submission

Location

DE929, Germany

Duration

Oct 2025 - Oct 2027

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Aug 21, 2027

Procurement Details

Publication date
02 Sep 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
573935-2025

Similar tenders